Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.

Rebecca L TisdaleMarika M CusickKelly Zhang AluriThomas J HandleyAlice Kate Cummings JoynerJoshua A SalomonGlenn M ChertowJeremy D Goldhaber-FiebertDouglas K Owens

Published in: Journal of general internal medicine (2022)

Dapagliflozin improved life expectancy and reduced progression of CKD, the proportion of patients requiring kidney replacement therapy, and time on kidney replacement therapy in patients with non-diabetic CKD. Use of dapagliflozin meets conventional criteria for cost-effectiveness.

Keyphrases

replacement therapy
chronic kidney disease
end stage renal disease
smoking cessation
type diabetes
peritoneal dialysis
ejection fraction
newly diagnosed
wound healing
prognostic factors
patient reported outcomes